SEARCH

SEARCH BY CITATION

References

  • Amowitz, L.L., Komaroff, A.L., Miletich, J.P. & Ridker, P.M. (1999) Factor V Leiden is not a risk factor for myocardial infarction among young women. Blood, 93, 14321433.
  • Ardissino, D., Peyvandi, F., Merlini, P.A., Colombi, E. & Mannucci, P.M. (1996) Factor V (Arg 506 –> Gln) mutation in young survivors of myocardial infarction. Thrombosis and Haemostasis, 75, 701702.
  • Arruda, V.R., Annichino-Bizzacchi, J.M., Goncalves, M.S. & Costa, F.F. (1997) Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thrombosis and Haemostasis, 78, 14301433.
  • Bertina, R.M., Koeleman, B.P., Koster, T., Rosendaal, F.R., Dirven, R.J., De Ronde, H., Van Der Velden, P.A. & Reitsma, P.H. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369, 6467.
  • Bloemenkamp, K.W., Rosendaal, F.R., Helmerhorst, F.M., Buller, H.R. & Vandenbroucke, J.P. (1995) Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet, 346, 15931596.
  • Bloemenkamp, K.W., Rosendaal, F.R., Helmerhorst, F.M. & Vandenbroucke, J.P. (2000) Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Archives of Internal Medicine, 160, 4952.
  • Burzotta, F., De Paciaroni, K.S.V., Chiusolo, P., Manzoli, A., Casorelli, I., Leone, A.M., Rossi, E., Leone, G., Maseri, A. & Andreotti, F. (2002) Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. European Heart Journal, 23, 2630.
  • Corral, J., Gonzalez-Conejero, R., Lozano, M.L., Rivera, J., Heras, I. & Vicente, V. (1997) The venous thrombosis risk factor 20210A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. British Journal of Haematology, 99, 304307.
  • Coulet, F., Godard, V., Verdy, E. & Soubrier, F. (2000) Lack of association of the prothrombin gene variant G20210A with myocardial infarction in Caucasian males. Thrombosis and Haemostasis, 83, 796797.
  • Croft, S.A., Daly, M.E., Steeds, R.P., Channer, K.S., Samani, N.J. & Hampton, K.K. (1999) The prothrombin 20210A allele and its association with myocardial infarction. Thrombosis and Haemostasis, 81, 861864.
  • Doggen, C.J., Cats, V.M., Bertina, R.M. & Rosendaal, F.R. (1998) Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation, 97, 10371041.
  • Dunn, N.R., Arscott, A., Thorogood, M., Faragher, B., De Caestecker, L., MacDonald, T.M., McCollum, C., Thomas, S. & Mann, R.D. (2000) Regional variation in incidence and case fatality of myocardial infarction among young women in England, Scotland and Wales. Journal of Epidemiology and Community Health, 54, 293298.
  • Eikelboom, J.W., Baker, R.I., Parsons, R., Taylor, R.R. & Van Bockxmeer, F.M. (1998) No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. Thrombosis and Haemostasis, 80, 878880.
  • Emmerich, J., Poirier, O., Evans, A., Marques-Vidal, P., Arveiler, D., Luc, G., Aiach, M. & Cambien, F. (1995) Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Lancet, 345, 321.
  • Farley, T.M., Collins, J. & Schlesselman, J.J. (1998) Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception, 57, 211230.
  • Ferraresi, P., Marchetti, G., Legnani, C., Cavallari, E., Castoldi, E., Mascoli, F., Ardissino, D., Palareti, G. & Bernardi, F. (1997) The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arteriosclerosis Thrombosis and Vascular Biology, 17, 24182422.
  • Franco, R.F., Maffei, F.H., Lourenco, D., Morelli, V., Thomazini, I.A., Piccinato, C.E., Tavella, M.H. & Zago, M.A. (1998) Factor V Arg306 –> Thr (factor V Cambridge) and factor V Arg306 –> Gly mutations in venous thrombotic disease. British Journal of Haematology, 103, 888890.
  • Fried, L.P., Borhani, N.O., Enright, P., Furberg, C.D., Gardin, J.M., Kronmal, R.A., Kuller, L.H., Manolio, T.A., Mittelmark, M.B. & Newman, A. (1991) The Cardiovascular Health Study: design and rationale. Annals of Epidemiology, 1, 263276.
  • Gardemann, A., Arsic, T., Katz, N., Tillmanns, H., Hehrlein, F.W. & Haberbosch, W. (1999) The factor II G20210A and factor V G1691A gene transitions and coronary heart disease. Thrombosis and Haemostasis, 81, 208213.
  • Hartge, P., Brinton, L.A., Rosenthal, J.F., Cahill, J.I., Hoover, R.N. & Waksberg, J. (1984) Random digit dialing in selecting a population-based control group. American Journal of Epidemiology, 120, 825833.
  • Herings, R.M., Urquhart, J. & Leufkens, H.G. (1999) Venous thromboembolism among new users of different oral contraceptives. Lancet, 354, 127128.
  • Holm, J., Zoller, B., Svensson, P.J., Berntorp, E., Erhardt, L. & Dahlback, B. (1994) Myocardial infarction associated with homozygous resistance to activated protein C. Lancet, 344, 952953.
  • Inbal, A., Freimark, D., Modan, B., Chetrit, A., Matetzky, S., Rosenberg, N., Dardik, R., Baron, Z. & Seligsohn, U. (1999) Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood, 93, 21862190.
  • Irani-Hakime, N., Tamim, H., Elias, G., Choueiry, S., Kreidy, R., Daccache, J.L. & Almawi, W.Y. (2001) Factor V R506Q mutation-Leiden: an independent risk factor for venous thrombosis but not coronary artery disease. Journal of Thrombosis and Thrombolysis, 11, 111116.
  • Kontula, K., Ylikorkala, A., Miettinen, H., Vuorio, A., Kauppinen-Makelin, R., Hamalainen, L., Palomaki, H. & Kaste, M. (1995) Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thrombosis and Haemostasis, 73, 558560.
  • Mansourati, J., Da Costa, A., Munier, S., Mercier, B., Tardy, B., Ferec, C., Isaaz, K. & Blanc, J.J. (2000) Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thrombosis and Haemostasis, 83, 822825.
  • Martinelli, I., Sacchi, E., Landi, G., Taioli, E., Duca, F. & Mannucci, P.M. (1998) High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. New England Journal of Medicine, 338, 17931797.
  • Martinelli, I., Taioli, E., Bucciarelli, P., Akhavan, S. & Mannucci, P.M. (1999) Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arteriosclerosis Thrombosis and Vascular Biology, 19, 700703.
  • Miller, S.A., Dykes, D.D. & Polesky, H.F. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research, 16, 1215.
  • Poort, S.R., Rosendaal, F.R., Reitsma, P.H. & Bertina, R.M. (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 88, 36983703.
  • Prohaska, W., Mannebach, H., Schmidt, M., Gleichmann, U. & Kleesiek, K. (1995) Evidence against heterozygous coagulation factor V 1691 G–> A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. Journal of Molecular Medicine, 73, 521524.
  • Ridker, P.M., Hennekens, C.H., Lindpaintner, K., Stampfer, M.J., Eisenberg, P.R. & Miletich, J.P. (1995a) Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. New England Journal of Medicine, 332, 912917.
  • Ridker, P.M., Miletich, J.P., Stampfer, M.J., Goldhaber, S.Z., Lindpaintner, K. & Hennekens, C.H. (1995b) Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation, 92, 28002802.
  • Ridker, P.M., Miletich, J.P., Hennekens, C.H. & Buring, J.E. (1997) Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. Journal of American Medical Association, 277, 13051307.
  • Ridker, P.M., Hennekens, C.H. & Miletich, J.P. (1999) G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation, 99, 9991004.
  • Rosendaal, F.R., Siscovick, D.S., Schwartz, S.M., Psaty, B.M., Raghunathan, T.E. & Vos, H.L. (1997a) A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood, 90, 17471750.
  • Rosendaal, F.R., Siscovick, D.S., Schwartz, S.M., Beverly, R.K., Psaty, B.M., Longstreth, Jr, W.T., Raghunathan, T.E., Koepsell, T.D. & Reitsma, P.H. (1997b) Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood, 89, 28172821.
  • Rosendaal, F.R., Doggen, C.J., Zivelin, A., Arruda, V.R., Aiach, M., Siscovick, D.S., Hillarp, A., Watzke, H.H., Bernardi, F., Cumming, A.M., Preston, F.E. & Reitsma, P.H. (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thrombosis and Haemostasis, 79, 706708.
  • Sidney, S., Petitti, D.B., Quesenberry, C.P. Jr, Klatsky, A.L., Ziel, H.K. & Wolf, S. (1996) Myocardial infarction in users of low-dose oral contraceptives. Obstetrics and Gynecology, 88, 939944.
  • Siscovick, D.S., Schwartz, S.M., Rosendaal, F.R. & Psaty, B.M. (1997) Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thrombosis and Haemostasis, 78, 712.
  • Smiles, A.M., Jenny, N.S., Tang, Z., Arnold, A., Cushman, M. & Tracy, R.P. (2002) No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the cardiovascular health study. Thrombosis and Haemostasis, 87, 614621.
  • Tanis, B.C., Van Den Bosch, M.A., Kemmeren, J.M., Cats, V.M., Helmerhorst, F.M., Algra, A., Van der Graaf, Y. & Rosendaal, F.R. (2001) Oral contraceptives and the risk of myocardial infarction. New England Journal of Medicine, 345, 17871793.
  • Thomson, D.M., Brown, N.N. & Clague, A.E. (1992) Routine use of hair root or buccal swab specimens for PCR analysis: advantages over using blood. Clinica Chimica Acta, 207, 169174.
  • Van Bockxmeer, F.M., Baker, R.I. & Taylor, R.R. (1995) Premature ischaemic heart disease and the gene for coagulation factor V. Nature Medicine, 1, 185.
  • Van de Water, N.S., French, J.K., Lund, M., Hyde, T.A., White, H.D. & Browett, P.J. (2000) Prevalence of factor V Leiden and prothrombin variant G20210A in patients age < 50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. Journal of American College of Cardiology, 36, 717722.
  • Vandenbroucke, J.P., Koster, T., Briet, E., Reitsma, P.H., Bertina, R.M. & Rosendaal, F.R. (1994) Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet, 344, 14531457.
  • Vandenbroucke, J.P., Bloemenkamp, K.W., Rosendaal, F.R. & Helmerhorst, F.M. (2000) Incidence of venous thromboembolism in users of combined oral contraceptives. Risk is particularly high with first use of oral contraceptives. British Medical Journal, 320, 5758.
  • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1997) Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet, 349, 12021209.